FebriDx® Method Comparison Study Protocol

Last updated: March 3, 2025
Sponsor: Lumos Diagnostics
Overall Status: Active - Recruiting

Phase

N/A

Condition

Respiratory Syncytial Virus (Rsv) Infection

Treatment

Rapid point of care test to detect host immune response in ARI

Clinical Study ID

NCT06746259
CLP-0019
  • Ages 12-64
  • All Genders

Study Summary

The goal of this observational study is to learn about the performance and ease of use of FebriDx when operated by persons without laboratory experience or training in patients with acute respiratory symptoms. The main question it aims to answer is:

• Is FebriDx accurate at differentiating bacterial from non-bacterial respiratory infections when used by untrained operators? Trained and untrained participants will run the FebriDx test on patients with respiratory symptoms to evaluate comparability.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject exhibits or reports a new onset measured temperature (oral or tympanic) ofgreater than or equal to 100.5°F/38°C within 3 days (72 hours) of enrollment or atthe visit

  • Subject has clinical suspicion for Acute Respiratory Infection and presents with atleast one (1) of the following new onset symptoms beginning ≤ 7 days of enrollment:runny nose, nasal congestion, sore throat, cough, hoarse voice or shortness ofbreath

Exclusion

Exclusion Criteria:

  • Subject is unable or unwilling to provide signed, Informed Consent

  • Subject is less than 12 years old or over 64 years old

  • Subject has a fever that started more than 3 days (> 72 hours) prior to enrollment

  • Subject has symptoms of Acute Respiratory Infection that started > 7 days ofenrollment

  • Subject is receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in the last 30 days

  • Subject is in an immunocompromised state (e.g. HIV) or taking immunosuppressive orchemotherapeutic medications in the last 30 days (e.g. oral steroids, Methotrexate,Cyclosporine, Antimetabolite chemotherapy, interferon therapy)

  • Subject has taken antibiotics or antiviral therapy in the last 14 days

  • Subject received a live viral immunization in the last 14 days

  • Subject has significant trauma or burns (> 5% total body surface area or fullthickness (3rd°)) in the last 30 days

  • Subject has had major surgery (requiring intravenous anesthesia and/or respiratoryassistance) in the last 30 days

  • Subject has a history of a myocardial infarction or stroke in the last 30 days

Study Design

Total Participants: 800
Treatment Group(s): 1
Primary Treatment: Rapid point of care test to detect host immune response in ARI
Phase:
Study Start date:
December 20, 2024
Estimated Completion Date:
June 15, 2025

Study Description

A prospective, multi-center, blinded observational study to demonstrate that the FebriDx test meets the CLIA statutory criteria for waiver by providing sufficient assurance that the addition of a new operator population (untrained) and environment of use (waived) will not adversely impact the performance or safety of the test.

The study aims to:

  • Demonstrate that FebriDx® Test is accurate and the operator can perform the test with a negligible risk of erroneous result.

  • As a secondary objective, ease-of-use objective data and subjective feedback relating to the device and its operator interface will be collected at the end of the study and assessed for comparability.

Connect with a study center

  • Ascada Health

    Fullerton, California 92835
    United States

    Active - Recruiting

  • Exer Urgent Care

    Pasadena, California 91105
    United States

    Site Not Available

  • L&C

    Miami, Florida 33144
    United States

    Active - Recruiting

  • L&C Medical

    Miami, Florida 33144
    United States

    Site Not Available

  • Trujillo Medical Center

    Miramar, Florida 33027
    United States

    Active - Recruiting

  • Hillcrest Medical Research, LLC

    Orange City, Florida 32763
    United States

    Active - Recruiting

  • Hometown Urgent Care and Research

    Beavercreek, Ohio 45430
    United States

    Active - Recruiting

  • HMG Clinical Research/Herrera Medical Group

    Bedford, Texas 76021
    United States

    Active - Recruiting

  • Ascada Health

    Katy, Texas 77494
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.